Presence or Absence of QTc Prolongation in @entity4783 - @entity1510 Among Youth With XXXX .

@entity1 @entity1165 @entity1166 @entity944 @entity4784 @entity1163 @entity4783 @entity1510 @entity2224 @entity284 @entity1162
OBJECTIVES: The aim of the study was to evaluate @entity4783 - @entity1510 effects on the QTc in youth with @entity4784 . @entity4783 is a partial agonist that is an effective treatment for @entity4784 . Compared with @entity284 , it has a lower risk of @entity1162 in adults, but is less studied in the youth. It may also reduce the risk of @entity1166 ( @entity1166 )-an uncommon variant of polymorphic @entity1165 -that can result in @entity1163 , @entity2224 , and @entity944 . METHODS: Secondary analysis of the electrocardiogram data from 95 individuals who participated in a multisite trial for youth with @entity4784 . The @entity1 were randomized to a 2-week (DETOX) or a 12-week course of @entity4783 - @entity1510 (BUP). At baseline, 12-lead electrocardiograms were done at weeks 4 and 12, and QTc intervals were hand-measured and calculated using Bazett formula. Increases above 60 milliseconds were considered clinically significant, and readings above 450 milliseconds (in @entity1 ) and 470 milliseconds (in @entity1 ) indicated a prolonged QTc. RESULTS: Mean QTc intervals were higher for BUP than for DETOX @entity1 at baseline, week 4, and week 12 (P=0.045), and @entity1 had longer mean QTc intervals than @entity1 (P<0.0005). Variations in the QTc intervals were observed in some; however, none were above 500 milliseconds-the level at which risk for @entity1166 becomes more significant. CONCLUSIONS: In this randomized trial, the mean QTc at baseline, before randomization, was higher in BUP than in DETOX @entity1 . Minimal changes in the QTc were seen at 4 and 12 weeks in a few @entity1 in both groups. There was no evidence that @entity4783 - @entity1510 alone increased the QTc to a level that increased the risk for @entity1166 .
